Disintegrin variants that bind specifically to one or more of 51 and v integrins, such as v1, v3, v5, v6 and v8, but with reduced binding activity to IIb3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an v integrin or an 51 integrin.

Disintegrin variants that bind specifically to one or more of 51 and v integrins, such as v=1, v3, v5, v6 and v8, but with reduced binding activity to IIb3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an v integrin or an 51 integrin.

Disintegrin variants that bind specifically to one or more of 51 and v integrins, such as v1, v3, v5, v6 and v8, but with reduced binding activity to IIb3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an v integrin or an 51 integrin.

The disclosure relates to an expression method of a Haemocoagulase Acutus (Halase) recombinant protein. The method includes the following steps: (1) optimizing a halase gene; (2) performing Polymerase Chain Reaction (PCR) amplification on an optimized halase gene; (3) constructing an Agkis-pMCX expression vector, transforming plasmids to competent cells of an escherichia coli for amplification, screening in an Amp-resistant manner for positive cloning, sequencing and extracting recombinant plasmids with correct sequencing; (4) transfecting recombinant plasmids to CHO cells; and (5) expressing the recombinant protein and identifying. According to the expression method, a recombinant halase is expressed first using the CHO cells cultured in a serum-free suspension manner; and by utilizing a bioengineering means, the actual production problems of insufficient raw material sources and unstable quality of a snake venom product are solved successfully.

A method for suppressing or inhibiting the growth of a cancer cell or tumor cell that expresses one or more integrins on its cell surface in a subject in need thereof is disclosed, herein, the method comprising administering to the subject an effective amount of contortrostatin (CN) and/or vicrostatin (VCN) or an equivalent of each thereof and wherein the CN and/or VCN or the equivalent of each thereof is conjugated to a therapeutic radioisotope.

The present invention relates to a novel recombinant batroxobin mixture, a hemostatic composition comprising the same, and a method for preparing the same. According to the present invention, the hemostatic composition of the present invention has an excellent hemostatic effect by suppressing rebleeding, and maintains activity thereof even when prepared in a solid form, and thus, the composition of the present invention can be easily used by being applied as a topical hemostatic agent.

Provided are a novel coagulation factor X activating enzyme, a pharmaceutical composition comprising same, and use thereof in preparing a medicament for treating hemorrhage or hemorrhagic diseases. Also provided is a method for purifying a coagulation factor X activating enzyme, which adopts a sequential combination of anion exchange chromatography and cation exchange chromatography, has higher yield while ensuring the high purity and high activity of the product, greatly improves the cost-efficiency, and is beneficial to large-scale industrial production.